Buy Kazia Therape Stock | NVGN Stock Price & Latest News | Public
NVGN

Kazia Therape

    We couldn’t load this chart.

    Some stock charts might currently not be supported. To try again, please refresh this page.

    About NVGN

    Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered i...Read more

    Buy any stock with any amount of money.

    Download the App
    Download the app

    Stats

    Market Cap$124,27M
    Volume
    Price-to-Earnings Ratio
    Dividend Rate
    Dividend Yield
    1 Year High$15.85
    1 Year Low$2.47
    Open
    High
    Low

    Buy any stock with any amount of money.

    Download the App
    Download the app